Omeros’ (OMER) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Omeros Co. (NASDAQ:OMER) in a research report sent to investors on Friday. Needham & Company LLC currently has a $22.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $24.00.

A number of other equities research analysts also recently issued reports on OMER. WBB Securities reaffirmed a buy rating and set a $75.00 price target on shares of Omeros in a research note on Thursday, November 17th. Zacks Investment Research raised shares of Omeros from a sell rating to a hold rating in a research note on Tuesday, November 22nd. Wedbush reaffirmed an outperform rating and set a $47.00 price target on shares of Omeros in a research note on Thursday, January 5th. Maxim Group reaffirmed a buy rating on shares of Omeros in a research note on Wednesday, March 1st. Finally, FBR & Co reaffirmed a buy rating on shares of Omeros in a research note on Thursday, March 2nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Omeros presently has an average rating of Buy and an average target price of $33.38.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Shares of Omeros (NASDAQ:OMER) traded up 12.90% during trading on Friday, reaching $11.90. 950,358 shares of the company were exchanged. The stock’s 50 day moving average is $11.05 and its 200 day moving average is $10.51. Omeros has a 1-year low of $7.20 and a 1-year high of $16.38. The company’s market capitalization is $510.69 million.

Your IP Address:

Several large investors have recently made changes to their positions in OMER. Norges Bank purchased a new stake in shares of Omeros during the fourth quarter valued at $744,000. Opaleye Management Inc. purchased a new stake in shares of Omeros during the fourth quarter valued at $2,632,000. Cpcm LLC purchased a new stake in shares of Omeros during the fourth quarter valued at $12,709,000. First Allied Advisory Services Inc. purchased a new stake in shares of Omeros during the fourth quarter valued at $108,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Omeros during the fourth quarter valued at $263,000. 47.94% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition


© 2006-2017 Ticker Report. Google+.